NASDAQ:TLGT Teligent (TLGT) Stock Price, News & Analysis → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free TLGT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.0552-Week Range N/AVolume6,460 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Teligent alerts: Email Address Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Teligent Stock (NASDAQ:TLGT)Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.Read More Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. TLGT Stock News HeadlinesApril 23, 2023 | wsj.comIDT Corp. Cl BJuly 18, 2022 | finance.yahoo.comLidocaine Market Size is projected to reach USD 3.05 Billion by 2029, growing at a CAGR of 8.45%: Straits Research - Yahoo FinanceJune 21, 2022 | law360.comRevlon Case Opens, And LATAM Lands Its Ch. 11 Plan - Law360June 17, 2022 | law360.comTeligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt - Law360May 3, 2022 | finance.yahoo.comTopical Drugs Market Size to Grow by USD 70.95 billion from 2021 to 2026 | Driven by Increase in the Prevalence of Skin Diseases | Technavio - Yahoo FinanceApril 27, 2022 | law360.comTeligent Gets Ch. 11 Disclosure, Voting Plans OK'd In Del. - Law360April 26, 2022 | law360.comUS Trustee Calls Teligent Ch. 11 Plan Releases 'Baffling' - Law360April 12, 2022 | law360.comTeligent OK'd For Fast-Tracked Del. Ch. 11 Disclosure Hearing - Law360April 1, 2022 | wsj.comAlex Mandl, Who Gave Up a Top AT&T Job to Lead a Startup, Has Died at Age 78 - The Wall Street JournalFebruary 28, 2022 | bizjournals.comTeligent seeks to convert bankruptcy to Chapter 7 amid impasse with creditors - Philadelphia Business Journal - Philadelphia Business JournalFebruary 25, 2022 | law360.comTeligent Says Stalled Plan Talks Make Liquidation Best Option - Law360February 9, 2022 | news.yahoo.comRobber to be resentenced because judge forgot to ask a question - Yahoo NewsFebruary 8, 2022 | law360.comTeligent Lender Slams Creditor Group Bid To Claw Back Cash - Law360February 3, 2022 | prnewswire.comPAI further bolsters its portfolio with the acquisition of Teligent Sterile Injectable and Topical products - PRNewswireFebruary 3, 2022 | morningstar.co.ukHikma completes acquisition of Teligent's Canadian... - MorningstarJanuary 19, 2022 | law360.comTeligent's 3 Ch. 11 Asset Sales Bring $87M Into Estate - Law360January 18, 2022 | law360.comTeligent's Three Ch. 11 Asset Sales Bring $87M Into Estate - Law360January 17, 2022 | marketwatch.comHikma to Buy Canadian Assets of Teligent for $45.75 Mln - MarketWatchJanuary 17, 2022 | lse.co.ukTOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million | Financial News - London South EastJanuary 17, 2022 | prnewswire.comHikma expands into Canada with acquisition of Teligent sterile injectable assets - PRNewswireDecember 14, 2021 | law360.com3-Part Ch.11 Stalking Horse Sale OK'd For Teligent - Law360December 8, 2021 | nasdaq.comFDA Approves Daré Bioscience's Xaciato For Bacterial Vaginosis - NasdaqDecember 8, 2021 | finance.yahoo.comRocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer - Yahoo FinanceDecember 2, 2021 | marketwatch.comAtropine Sulfate Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2028November 11, 2021 | wsj.comPlaintiffs Want Teligent Price-Fixing Lawsuit to Continue Despite Bankruptcy - The Wall Street JournalSee More Headlines Receive TLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teligent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2021Today5/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TLGT CUSIPN/A CIK352998 Webwww.teligent.com Phone(856) 697-1441Fax856-697-1442Employees2,357Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesTimothy B. SawyerPresident, Chief Executive Officer & DirectorAntonio di NicolaVice President-Operations & General ManagerAlyssa LozynskiChief Financial OfficerDevendra ShahVice President-Research & DevelopmentPhilip K. YachmetzSecretary, Chief Legal Officer & Executive VPKey CompetitorsLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPOncoSec MedicalNASDAQ:ONCSQPharvarisNASDAQ:PHVSView All Competitors TLGT Stock Analysis - Frequently Asked Questions How were Teligent's earnings last quarter? Teligent, Inc. (NASDAQ:TLGT) announced its earnings results on Monday, August, 16th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company earned $10.43 million during the quarter. When did Teligent's stock split? Teligent's stock reverse split on the morning of Thursday, May 28th 2020. The 1-10 reverse split was announced on Wednesday, May 27th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tim Sawyer's approval rating as Teligent's CEO? 2 employees have rated Teligent Chief Executive Officer Tim Sawyer on Glassdoor.com. Tim Sawyer has an approval rating of 100% among the company's employees. This puts Tim Sawyer in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Teligent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX), ChemoCentryx (CCXI), Voyager Therapeutics (VYGR), AbbVie (ABBV), General Electric (GE), Biocept (BIOC), Lannett (LCI), Pfizer (PFE), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). This page (NASDAQ:TLGT) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teligent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.